The Technical Analyst
Seres Therapeutics Inc [MCRB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Seres Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
21.68% $0.760
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 114.77 mill |
| EPS: | -0.890 |
| P/E: | -0.850 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 151.01 mill |
| Avg Daily Volume: | 3.91 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.850 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.14x |
| Company: PE -0.850 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.694 - 0.826 ( +/- 8.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Graves Kurt | Buy | 60 000 | Stock Option (right to buy) |
| 2024-04-04 | Kender Richard N | Buy | 60 000 | Stock Option (right to buy) |
| 2024-04-04 | Biondi Paul | Buy | 60 000 | Stock Option (Right to Buy) |
| 2024-04-04 | Fraser Claire | Buy | 60 000 | Stock Option (right to buy |
| 2024-04-04 | Dere Willard H | Buy | 60 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 92.36 |
| Last 99 transactions |
| Buy: 7 007 921 | Sell: 289 369 |
Forecast:
16:00 - $0.765
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.765
Forecast 2: 16:00 - $0.765
Forecast 3: 16:00 - $0.765
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.760 (21.68% ) |
| Volume | 11.82 mill |
| Avg. Vol. | 3.91 mill |
| % of Avg. Vol | 301.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MCRB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.045 | N/A | Active |
|---|
MCRB
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-09 07:00:00 - Press Release
Seres Therapeutics Announces Completion Of Patient Enrollment For Ser-155 Phase 1b Cohort 2 Clinical Trial In Allogenic Hsct
Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled cohort 2 of its phase 1b trial of ser-155 in patients who received allogeneic hematopoietic stem cell transplantation (allo hsct). ser-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting.
2024-03-28 07:00:00 - Press Release
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on march 25, 2024, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 700,000 shares of its common stock to marella thorell, the company's new executive vice president and chief financial officer, consisting entirely of stock options. these stock options are.
2024-03-19 07:00:00 - Press Release
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on march 13, 2024, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“rsus”) covering 2,063 shares of its.
2024-03-05 07:00:00 - Press Release
Seres Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Updates
Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. “2023 was an historic year for seres as we launched our first-in-class oral microbiome therapeutic, vowst, for recurrent cdi into commercialization with our collaborators at nestlÉ health science,” said eric shaff, president and chief executive officer of seres. “we are proud of th.
2024-02-28 07:00:00 - Press Release
Seres Therapeutics To Host Fourth Quarter 2023 Financial Results And Operational Progress Conference Call And Webcast On March 5, 2024
Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on march 5, 2024 at 8:30 a.m. et to discuss fourth quarter and full year 2023 results and provide a general business update. to access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference id number 4030622. to join the live webcast,.
Latest News
2024-03-05 15:33:08 - Seeking Alpha
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege - CTO Matthew Henn - Chief Scientific Officer Conference Call Participants Jeff Jones - Oppenheimer John Newman - Canaccord Tess Romero - JPMorgan Peyton Bohnsack - TD Cowen Chris Shibutani - Goldman Sachs Keay Nakae - Chardan Operator Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today.
2024-03-05 10:18:44 - InvestorPlace
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally yesterday. The increasing price of gold is catching up to its current record high of $2,135.40 that was achieved in December 2023.
2023-11-28 09:18:00 - Business Wire
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archi.
2023-11-04 11:52:09 - Seeking Alpha
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference Call Participants Joseph Thome - TD Cowen Edward Tenthoff - Piper Sandler Tessa Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Stephen Sloan - Goldman Sachs Operator Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
2023-10-30 17:30:00 - Business Wire
Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET. The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference cal.
2023-09-01 14:03:22 - Seeking Alpha
Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent Clostridioides difficile infection. Seres Therapeutics' partnership with Nestle provides financial backing and distribution support, highlighting the potential of its drug VOWST.
2023-08-08 09:55:49 - Zacks Investment Research
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
Seres Therapeutics (MCRB) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to loss of $0.70 per share a year ago.
2023-06-07 11:16:58 - PennyStocks
Best Penny Stocks To Buy? 5 With Big News This Week
Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.
2023-06-02 07:00:00 - Business Wire
Seres Therapeutics to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ET in New York City. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will b.
2023-05-09 09:57:07 - Zacks Investment Research
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.